CP
TNGX icon

Caligan Partners’s Tango Therapeutics TNGX Stock Holding History

Caligan Partners’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.2M Buy
2,500,103
+91,305
+4% +$2.26M 3.68% 6
2026
Q1 		$50.4M Sell
2,408,798
-1,321,097
-35% -$18.4M 3.35% 9
2025
Q4 		$33M Buy
+3,729,895
New +$32.1M 2.72% 9

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Caligan Partners's TNGX Position: Q2 2026 in Review

Caligan Partners increased its Tango Therapeutics (TNGX) stake by 3.8% in Q2 2026, buying an estimated $2.26M and bringing the position to 2,500,103 shares worth $78.2M. The position accounts for 3.68% of the portfolio, ranked #6.

Caligan Partners first reported a position in TNGX in Q4 2025 and has held it in 3 quarters since. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Caligan Partners held 2,500,103 shares of Tango Therapeutics worth $78.2M as of Q2 2026.
  • Caligan Partners bought 91,305 Tango Therapeutics shares in Q2 2026, an estimated $2.26M.
  • Tango Therapeutics made up 3.68% of Caligan Partners's portfolio in Q2 2026, its #6 holding.
  • Caligan Partners first reported a position in Tango Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Caligan Partners's 13F filing for Q2 2026, filed 14 Aug 2026.